Last reviewed · How we verify
Cytarabine-Venetoclax Association
Cytarabine-Venetoclax Association works by combining cytarabine's DNA synthesis inhibition with venetoclax's selective inhibition of BCL-2 protein, leading to enhanced apoptosis in leukemia cells.
Cytarabine-Venetoclax Association works by combining cytarabine's DNA synthesis inhibition with venetoclax's selective inhibition of BCL-2 protein, leading to enhanced apoptosis in leukemia cells. Used for Acute Myeloid Leukemia (AML) in adults who are ineligible for intensive chemotherapy.
At a glance
| Generic name | Cytarabine-Venetoclax Association |
|---|---|
| Sponsor | French Innovative Leukemia Organisation |
| Drug class | Antimetabolite and BCL-2 inhibitor combination |
| Target | BCL-2, DNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Cytarabine inhibits DNA synthesis by acting as an antimetabolite, while venetoclax selectively binds to BCL-2, a protein that prevents apoptosis, thereby promoting cell death in cancer cells. The combination enhances the cytotoxic effect against leukemia cells.
Approved indications
- Acute Myeloid Leukemia (AML) in adults who are ineligible for intensive chemotherapy
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
- Venetoclax Basket Trial for High Risk Hematologic Malignancies (PHASE1)
- Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage (PHASE3)
- Venetoclax + Azacitidine vs. Induction Chemotherapy in AML (PHASE2)
- Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: